Name (Synonyms) | Correlation | |
---|---|---|
drug560 | Chloroquine Wiki | 0.25 |
drug2794 | current IPAC-UHN PPE Wiki | 0.24 |
drug173 | Angiotensin II Wiki | 0.24 |
drug1708 | Other drugs Wiki | 0.24 |
drug2350 | Standard treatment for COVID-19 Wiki | 0.24 |
drug2870 | liposomal lactoferrin Wiki | 0.24 |
drug2921 | non interventional Wiki | 0.24 |
drug1229 | Interleukin-1 receptor antagonist Wiki | 0.24 |
drug212 | Artemesia annua Wiki | 0.24 |
drug2202 | Sars-Cov-2 serology Wiki | 0.24 |
drug385 | Blood samples collection Wiki | 0.24 |
drug352 | Biological test Wiki | 0.24 |
drug2109 | Robot Assisted Percutaneous Cardiovascular Intervention Wiki | 0.24 |
drug570 | Cholecalciferol Wiki | 0.24 |
drug2859 | iota carrageenan Wiki | 0.24 |
drug1603 | Nitazoxanide with ivermectin Wiki | 0.24 |
drug1423 | Machine learning model Wiki | 0.24 |
drug1935 | Proxalutamide Wiki | 0.24 |
drug2896 | modified IPAC-UHN PPE Wiki | 0.24 |
drug1889 | Powered Air purifying respirator Wiki | 0.24 |
drug799 | Dutasteride Wiki | 0.24 |
drug1283 | Ivermectin wth chloroquine Wiki | 0.24 |
drug2004 | RO6953958 Wiki | 0.24 |
drug1592 | Niclosamide Wiki | 0.17 |
drug652 | Convalescent Plasma Transfusion Wiki | 0.17 |
drug1598 | Nitazoxanide Wiki | 0.17 |
drug1117 | Hydroxychloroquine and Azithromycin Wiki | 0.17 |
drug285 | BCG vaccine Wiki | 0.14 |
drug290 | BI 894999 Wiki | 0.14 |
drug262 | Azithromycin Wiki | 0.12 |
drug1219 | Interferon Beta-1A Wiki | 0.12 |
drug791 | Doxycycline Wiki | 0.12 |
drug2187 | Saliva collection Wiki | 0.11 |
drug512 | Camostat Mesilate Wiki | 0.11 |
drug698 | DAS181 Wiki | 0.10 |
drug1822 | Placebo Wiki | 0.09 |
drug1374 | Losartan Wiki | 0.08 |
drug1086 | Hydroxychloroquine Wiki | 0.07 |
drug923 | Favipiravir Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D010146 | Pain NIH | 0.24 |
D011470 | Prostatic Hyperplasia NIH | 0.24 |
D006965 | Hyperplasia NIH | 0.24 |
D002658 | Developmental Disabilities NIH | 0.24 |
D001416 | Back Pain NIH | 0.24 |
D003327 | Coronary Disease NIH | 0.24 |
D017116 | Low Back Pain NIH | 0.24 |
D011001 | Pleuropneumonia NIH | 0.24 |
D065886 | Neurodevelopmental Disorders NIH | 0.17 |
D000505 | Alopecia NIH | 0.17 |
D002659 | Child Development Disorders, Pervasive NIH | 0.14 |
D001321 | Autistic Disorder NIH | 0.12 |
D006331 | Heart Diseases NIH | 0.12 |
D003324 | Coronary Artery Disease NIH | 0.12 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.11 |
D018352 | Coronavirus Infections NIH | 0.11 |
D002277 | Carcinoma NIH | 0.11 |
D000067877 | Autism Spectrum Disorder NIH | 0.10 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.08 |
D009203 | Myocardial Ischemia NIH | 0.08 |
D008173 | Lung Diseases, Obstructive NIH | 0.08 |
D007239 | Infection NIH | 0.07 |
D013577 | Syndrome NIH | 0.05 |
D001523 | Mental Disorders NIH | 0.05 |
D055371 | Acute Lung Injury NIH | 0.05 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.05 |
D004194 | Disease NIH | 0.04 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.04 |
D014777 | Virus Diseases NIH | 0.03 |
D003141 | Communicable Diseases NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0003418 | Back pain HPO | 0.24 |
HP:0008711 | Benign prostatic hyperplasia HPO | 0.24 |
HP:0012531 | Pain HPO | 0.24 |
HP:0003419 | Low back pain HPO | 0.24 |
HP:0002293 | Alopecia of scalp HPO | 0.17 |
HP:0001677 | Coronary artery atherosclerosis HPO | 0.12 |
HP:0000717 | Autism HPO | 0.12 |
HP:0030731 | Carcinoma HPO | 0.11 |
HP:0000729 | Autistic behavior HPO | 0.10 |
HP:0001658 | Myocardial infarction HPO | 0.08 |
HP:0006510 | Chronic pulmonary obstruction HPO | 0.08 |
HP:0006536 | Pulmonary obstruction HPO | 0.08 |
There are 18 clinical trials
COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.
Description: the estimated number of patients with decreased viral load
Measure: Number of patients with decreased viral load Time: 6 monthsEfficacy of Ivermectin and Nitazoxanide in COVID-19 treatment
Description: The number of patients with improvement or death
Measure: Number of patients with improvement or died Time: 1 monthAt present, there are no specific treatments for COVID-19. WHO recommends four treatments for COVID 19 with drugs i.eRemdesivir, Lopinavir/ ritonavir, Lopinavir/ ritonavir with interferon beta -1a, and chloroquine or hydroxychloroquine. Currently, there are several ongoing clinical trials evaluating potential treatments. Recently, LeonCaly reported that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARSCoV-2 able to effect about 5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrant further investigation for possible benefits in humans. The study rationale is to understand the effect of the drug on eradication of virus.
Description: Test for virus at 1, 3 & 5 days from beginning of trial drug started for the patient in the hospital
Measure: effect of Ivermectin on eradication of virus. Time: 3 monthsThis is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.
Description: Proportion of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes.
Measure: Clinical Deterioration Time: 14 daysDescription: The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days.
Measure: Change in Viral Load Time: 40 daysDescription: Percentage of patients that experience severe respiratory or other organ failure.
Measure: Rate of Organ Failure Time: 28 daysDescription: Percentage of patients requiring ICU admission or ventilation.
Measure: Progression to ICU Care or Ventilation Time: 28 daysDescription: Clinical status will be assessed using the COVID 7-Point Ordinal Outcomes Scale. This scale ranges from 1-7. Lower scores indicate worse outcomes; higher scores indicate fewer symptoms and better outcomes.
Measure: Change in Clinical Status Time: 14 daysDescription: Percentage of patients who have died by day 14.
Measure: Mortality Time: 14 daysDescription: Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events.
Measure: Rate of severe adverse events Time: 14 daysDescription: Number of days patients do not require oxygen supplementation.
Measure: Oxygen-free days Time: 28 daysDescription: Number of days patients do not require mechanical ventilation.
Measure: Ventilator-free days Time: 28 daysDescription: Number of days patients do not require vasopressor treatment.
Measure: Vasopressor-free days Time: 28 daysDescription: Number of days patients do not require ICU services.
Measure: ICU-free days Time: 28 daysDescription: Number of days patients do not require hospitalization.
Measure: Hospital-free days Time: 28 daysDescription: Proportion of patients meeting Hy's law criteria.
Measure: Patients meeting Hy's Law criteria Time: 28 daysDescription: Proportion of patients with changes in the following liver function tests: Any ALT or AST ≥ 5 x ULN; any AST or ALT ≥ 3 x ULN together with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (eosinophil percent or count above the ULN); Persistent ALT ≥ 3 x ULN for a period of more than 4 weeks
Measure: Liver Function Time: 28 daysDescription: Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms.
Measure: Heart Function Time: 28 daysAzithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Description: the number of patients with virological cure
Measure: Number of patients with virological cure Time: 6 monthsSAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease. The trial is currently planned at a single center in Navarra.
Description: Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment
Measure: Proportion of patients with a positive SARS-CoV-2 PCR Time: 7 days post-treatmentDescription: Change from baseline quantitative and semi-quantitative PCR in nasopharyngeal swab
Measure: Mean viral load Time: Baseline and on days 4, 7, 14 and 21Description: Proportion of patients with fever and cough at days 4, 7, 14 and 21 as well as proportion of patients progressing to severe disease or death during the trial
Measure: Fever and cough progression Time: Up to and including day 21Description: Proportion of participants with positive IgG at day 21
Measure: Seroconversion at day 21 Time: Up to and including day 21Description: Proportion of drug-related adverse events
Measure: Proportion of drug-related adverse events Time: 7 days post treatmentDescription: Levels in median fluorescence intensity (MFI) of IgG, IgM and IgA against the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 in plasma, measured by a Luminex assay
Measure: Levels of IgG, IgM and IgA Time: Up to and including day 28Description: Frequency (% over total PBMC) of innate immune cells (myeloid and plasmacytoid dendritic cells, NK cell, classical, intermediate and pro-inflammatory macrophages) measured in cryopreserved PBMC by flow cytometry
Measure: Frequency of innate immune cells Time: Up to and including day 7Description: Frequency of CD4+ T and CD8+ T cells (% over total CD4+T and CD8+ T) expressing any functional marker upon in vitro stimulation of PBMC with SARS-CoV-2 peptides, measured by flow cytometry
Measure: Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells Time: Up to and including day 7Description: Concentration (all in pg/mL) of epidermal growth factor (EGF), fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1RA, IL-1β, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p40/p70), IL-13, IL-15, IL-17, IFN-γ induced protein (IP-10), monocyte chemoattractant protein (MCP-1), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-1β in plasma measured by a Luminex assay using a commercially available kit (Cytokine Human Magnetic 30-Plex Panel from ThermoFisher)
Measure: Results from cytokine Human Magnetic 30-Plex Panel Time: Up to and including day 28Background: In December 2019, patients with pneumonia secondary to a new subtype of Coronavirus (COVID-19) were identified in China. In a few weeks the virus spread and cases started practically all over the world. In February 2020, the WHO declared a pandemic. Severe symptoms have been found in patients mainly with comorbidities and over 50 years of age. At this time there is no proven therapeutic alternative. In vitro studies and observational experiences showed that antimalarial drugs (Chloroquine and hydroxychloroquine) had antiviral activity and increased viral clearance. Ivermectin, on the other hand, has been shown in vitro to reduce viral replication and in an observational cohort, greater viral clearance with promising clinical results. So far there is no standard of treatment and clinical trials are needed to find effective treatment alternatives. Objective: To evaluate the safety and efficacy of treatment with hydroxychloroquine and ivermectin for serious COVID-19 infections in no critical hospitalized patients. Material and methods: Randomized controlled trial of patients diagnosed with respiratory infection by COVID-19, who present criteria for hospitalization. Randomization will be performed to receive hydroxychloroquine at a dose of 400 mg every 12 hours for one day and then 200 mg every 12 hours, to complete a 5-day treatment schedule. Group 2: Ivermectin 12 mg every 24 hours for one day (less than 80 kg) or Ivermectin 18 mg every 24 hours for one day (greater than 80 kg) + placebo until the fifth day. Group 3: Placebo. Prior to randomization, the risk of cardiovascular complications determined by corrected QT interval, related to hydroxychloroquine intake will be assessed. If the patient is at high risk, the allocation will be to ivermectin only or to placebo in an independent randomization, if the risk is low, any of the three groups could be assigned. Outcomes: The primary outcome will be discharge from hospital for improvement. The safety outcomes will be requirement of mechanical intubation, septic shock or death. Viral clearance will also be evaluated by means of PCR, which will be taken on the 5th day after admission, day 14 and 21.
Description: Days from admission as a suspected case of COVID with hospitalization criteria until discharge
Measure: Mean days of hospital stay Time: Three monthsDescription: Respiratory deterioration defined by respiratory rate > 25 per minute, requirement of high oxygen supply (FiO2 > 80% ) to maintain oxygen saturation > 90 %, invasive mechanical ventilation or dead.
Measure: Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead Time: Three monthsDescription: Daily delta of oxygenation index during the hospitalization
Measure: Mean of oxygenation index delta Time: Three monthsDescription: Mean time to viral negativization of RT-qPCR SARS-CoV-2. Pre Specified time: 5, 14, 21 and 28 days after the first positive PCR.
Measure: Mean time to viral PCR negativization Time: 5, 14, 21 and 28 days after the first positive PCRAs the world faces COVID-19, the search for effective treatments against the disease and its complications has turned its gaze to drugs that are classically used in other infectious diseases. Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation, one is Azithromycin, used to treat a wide variety of bacterial infections, Ivermectin, an anti-parasitic drug and the other is Cholecalciferol to increase serum concentration of 25-hydroxyvitamin D.
Description: Test for virus at day 1 and 14 from beginning of trial drug started
Measure: Viral clearance Time: 14 daysDescription: The duration of symptoms in days
Measure: Symptoms duration Time: 14 daysDescription: oxygen saturation
Measure: SpO2 Time: 14 daysDescription: Oxygen Saturation (SpO2)/Fraction of Inspired Oxygen (FiO2) Ratio
Measure: SpO2/FiO2 Time: 14 daysEfficacy of Ivermectin and Doxycycline in COVID-19 treatment
Description: The number of patients with improvement or mortality
Measure: The number of patients with improvement or mortality Time: 1 monthThis study aims to evaluate the efficacy, safety and tolerability of Ivermectin in patients with mild SARS-CoV-2 infection, in the rate of progression to severe 2019 novel coronavirus disease (COVID-19). The primary efficacy endpoint is the proportion of participants with a disease control status defined as no progression of severe disease Hypothesis (H0): There is no difference between group A (ivermectin + paracetamol) and group B (ivermectin + paracetamol) in terms of the primary endpoint on day 14.
Description: The subject is considered to have progressed to severe illness when one or more of the following criteria are present: Breathing difficulty (≥30 breaths per minute); Resting oxygen saturation ≤93%; Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.
Measure: Participants with a disease control status defined as no disease progression to severe. Time: 14 daysas Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment
Description: the role of ivermectin in the cure of COVID 19 patients
Measure: to evaluate the role of Ivermectin as a line of treatment for COVID 19 Time: 2 monthsDescription: to compare the results of ivermectin with the standard care
Measure: To asses the rate of viral clearance in comparison to other treatment protocols. Time: 2 monthsEstimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease. It is estimated that 86% of all infections were undocumented [95% credible interval (CI): 82-90%] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases. Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.
Description: For Health Personnel, the average dessertion all over the world has raised to 27 % worldwide. We aim at reducing it dramaticaly.
Measure: Reduction in contagion Time: 30 daysDescription: Allergy to any of the two drugs administered topically
Measure: Secondary and or side effects Time: 7 daysIn December 2019, a group of patients with pneumonia of unknown cause was linked to a wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower respiratory tract of these patients indicated a new coronavirus as the causative agent, which was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil, causing an international alarm. However, in spite of its epidemiological magnitude, so far, there is no antiviral treatment or vaccine approved for the treatment of this infection. With about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened hospitals, therapeutic options are desperately needed. So, instead of creating compounds from scratch that can take years to develop and test, researchers and public health agencies have sought to redirect drugs already approved for other diseases and known to be widely safe. In this context, the analysis of the international literature shows the existence of an in vitro antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection. Therefore, and considering this knowledge gap, the present study aims to determine the clinical efficacy and safety of different doses of ivermectin in patients diagnosed with SARS-CoV-2 infection.
Description: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab after Intervention Initiation.
Measure: Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab. Time: 7 days following interventionDescription: Viral load variation in the nasopharyngeal swab during treatment.
Measure: Viral load variation in the nasopharyngeal swab. Time: 7 days following intervention.Description: Variation of serum lymphocyte counts during treatment.
Measure: Variation of serum lymphocyte counts. Time: 7 days following intervention.Description: Variation of serum AST/ALT values during treatment.
Measure: Variation of serum AST/ALT values. Time: 7 days following intervention.Description: Variation of serum D-dimer values during treatment.
Measure: Variation of serum D-dimer values. Time: 7 days following intervention.Description: Variation of serum CPK values during treatment.
Measure: Variation of serum CPK values. Time: 7 days following intervention.Description: Variation of serum LDH values during treatment.
Measure: Variation of serum LDH values. Time: 7 days following intervention.Description: Time to clinical improvement, defined as the time to normalize fever, respiratory rate and oxygen saturation and cough relief in at least 72 hours;
Measure: Time to clinical improvement Time: 7 days following intervention.Prospective, multi-centre, randomized, double-blind trial to assess efficacy and safety of ivermectin for the treatment of initial infection with SARS-CoV2 infection. Study arms: A) placebo B) ivermectin 600 μg/kg daily for 5 consecutive days (I_600) + placebo. C) ivermectin 1200 μg/kg daily at empty stomach with water for 5 consecutive days (I_1200). Patients will be randomized at emergency room of hospitals as well as at outpatient ambulatory care as well as at home, according to routine procedures of recruiting centres. In arm A and B, the number of placebo tablets to be administered will be calculated by the study dedicated pharmacist considering the number of tablets that should be taken in case a patient with the same weight is assigned to arm C.
Description: Number of serious adverse drug reaction
Measure: SADR Time: 14 daysDescription: Quantitative viral load as measured by quantitative, digital droplet PCR.
Measure: Viral load Time: Assessed at day 7Description: 1. Trend over time of quantitative viral load at Day 7 and 14 as measured by quantitative, digital droplet PCR.
Measure: Trend viral load Time: Days 7 and 14 from baselineDescription: Time to clinical resolution (for symptomatic patients).
Measure: Clinical resolution Time: Assessed on Day 30Description: Time from diagnosis to documented viral clearance
Measure: Viral clearance Time: assessed on days 14 and 30Description: Proportion of patients with virological clearance
Measure: Virological clearance Time: Assessed at day 14 and 30Description: rate of hospitalization
Measure: hospitalization rate Time: Day 30Description: COVID-19 Severity Score (Coronavirus Diseases 19 Severity Score) - min value 1 ("no limitation of activities), max value 8 ("death"). Higher scores mean worse outcome
Measure: Severity score Time: Assessed at Day 14 and Day 30confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt
Description: duration from day 1 symptoms till 3 days without symptoms
Measure: time to be symptoms free Time: within 21 days after enrollmentDescription: need hospital admission
Measure: hospitalization Time: within 21 days after enrollementDescription: need mechanical ventilation
Measure: Mechanical ventilation Time: within 21 days after enrollementDescription: days spent in hospital
Measure: length of stay Time: within one month days after enrollementDescription: survived or died
Measure: mortality Time: within one month days after enrollementThis study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
Description: Percentage of subjects hospitalized due to COVID-19
Measure: COVID-19 hospitalization Time: 30 daysDescription: COVID Ordinal Scale defined as: Death Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation) Hospitalized on non-invasive ventilation or high flow nasal cannula Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with limitation in activity (continued symptoms) Not hospitalized without limitation in activity (no symptoms)
Measure: COVID-19 Ordinal Outcomes Scale Time: 30 daysDescription: Symptoms severity of COVID-19 using Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm
Measure: Symptoms severity of COVID-19 Time: 30 daysIvermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19
Description: Incidence of severe complications due COVID-19 infection defined as need for ICU admission, need for mechanical ventilation, or death
Measure: Incidence of severe complications due COVID-19 infection Time: 28 daysDescription: Severe Acute Respiratory Syndrome defined as oxygen saturation less than 93%
Measure: Incidence of Severe Acute Respiratory Syndrome Time: 28 daysDescription: Severe Acute Respiratory Syndrome defined as respiratory rate higher than 24 incursion per minute
Measure: Incidence of Severe Acute Respiratory Syndrome Time: 28 daysDescription: Incidence of hepatic toxicity (elevation of ALT, AST above the upper limit of normal, measured by U/L)
Measure: Adverse events Time: 28 daysDescription: Incidence of hepatic toxicity (elevation of bilirubin above the upper limit of normal, measured by mg/dL)
Measure: Adverse events Time: 28 daysDescription: Incidence of renal toxicity (elevation of serum creatinine levels above the upper limit of normal, measured by mg/dL)
Measure: Adverse events Time: 28 daysDescription: Incidence of symptomatic postural hypotension, diagnosed by clinical assessment of reduction of > 20 mmHG of arterial systolic pressure after measurement in prone position and orthostatic position.
Measure: Adverse events Time: 28 daysDescription: Death of any cause since protocol enrollment
Measure: Overall survival Time: 28 daysOn 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.
Description: To understand the geographical distribution of the interventional studies after 11th of March 2020.
Measure: Geographical distribution of the interventional studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the geographical distribution of the Observational studies after 11th of March 2020.
Measure: Geographical distribution of the Observational studies after 11th of March 2020. Time: 15th of August 2020Description: To understand the monthly Research study completion rate as per geographic distribution of the Research.
Measure: Monthly Research study completion rate as per geographic distribution of the Research. Time: 15th of August 2020Description: To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the observational studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020Description: To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
Measure: Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries. Time: 15th of August 2020